

Edgar Filing: PRO DEX INC - Form 10-Q

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company under Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer

Non-accelerated filer Smaller reporting company

Indicate whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate the number of shares outstanding of each of the Registrant's classes of Common Stock outstanding as of the latest practicable date: 3,342,321 shares of Common Stock, no par value, as of January 31, 2014.

Table of Contents

INDEX

Pro-Dex, Inc.

<u>Part I. Financial Information</u>	3
<u>Item 1. Financial Statements (unaudited):</u>	3
<u>Condensed consolidated balance sheets — December 31, 2013 and June 30, 2013</u>	3
<u>Condensed consolidated statements of operations and comprehensive loss — Three months ended December 31, 2013 and 2012</u>	4
<u>Condensed consolidated statements of operations and comprehensive income (loss) — Six months ended December 31, 2013 and 2012</u>	5
<u>Condensed consolidated statements of cash flows — Six months ended December 31, 2013 and 2012</u>	6
<u>Notes to unaudited condensed consolidated financial statements</u>	7
<u>Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	15
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	21
<u>Item 4. Controls and Procedures</u>	21
<u>Part II. Other Information</u>	21
<u>Item 1. Legal Proceedings</u>	21
<u>Item 1A. Risk Factors</u>	22
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	22
<u>Item 3. Defaults Upon Senior Securities</u>	22
<u>Item 4. Mine Safety Disclosures</u>	22
<u>Item 5. Other Information</u>	22
<u>Item 6. Exhibits</u>	22
<u>Signatures</u>	23

Table of Contents

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

PRO-DEX, INC. and SUBSIDIARIES
 CONDENSED CONSOLIDATED BALANCE SHEETS
 (unaudited)

	December 31, 2013	June 30, 2013
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 1,554,000	\$ 1,680,000
Accounts receivable, net of allowance for doubtful accounts of \$31,000 at December 31, 2013 and \$24,000 at June 30, 2013	1,580,000	1,339,000
Unbilled receivables	611,000	244,000
Other current receivables	43,000	32,000
Inventories	3,552,000	3,834,000
Prepaid expenses	168,000	157,000
Income taxes receivable	7,000	2,000
Deferred income taxes	60,000	59,000
Total current assets	7,575,000	7,347,000
Investments	903,000	370,000
Equipment and leasehold improvements, net	1,794,000	2,065,000
Real estate held for sale	—	733,000
Intangibles	40,000	—
Other assets	77,000	80,000
Total assets	\$ 10,389,000	\$ 10,595,000
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 626,000	\$ 844,000
Accrued expenses	1,089,000	1,276,000
Deferred revenue	247,000	141,000
Income taxes payable	48,000	48,000
Capital lease obligations	7,000	5,000
Total current liabilities	2,017,000	2,314,000
Non-current liabilities:		
Deferred income taxes	60,000	59,000
Deferred rent	253,000	270,000
Capital lease obligations	12,000	15,000
Total non-current liabilities	325,000	344,000
Total liabilities	2,342,000	2,658,000
Commitments and contingencies		
Shareholders' equity:		
Common shares; no par value; 50,000,000 shares authorized; 3,342,321 and 3,348,184 shares issued and outstanding at December 31, 2013 and June 30, 2013, respectively	17,044,000	17,012,000

Edgar Filing: PRO DEX INC - Form 10-Q

Accumulated other comprehensive income	209,000	5,000
Accumulated deficit	(9,206,000) (9,080,000)
Total shareholders' equity	8,047,000	7,937,000
Total liabilities and shareholders' equity	\$ 10,389,000	\$ 10,595,000

See notes to unaudited condensed consolidated financial statements.

Table of ContentsPRO-DEX, INC. and SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**(unaudited)**

	For the Three Months Ended December 31,	
	2013	2012
Net sales	\$2,640,000	\$3,007,000
Cost of sales	2,091,000	1,974,000
Gross profit	549,000	1,033,000
Operating expenses:		
Selling expenses	139,000	322,000
General and administrative expenses	422,000	627,000
Research and development costs	364,000	464,000
Total operating expenses	925,000	1,413,000
Loss from continuing operations before items below	(376,000)	(380,000)
Other expense (income):		
Interest expense	2,000	—
Interest income	(10,000)	—
Loss from disposal of equipment	6,000	—
Total other expense (income)	(2,000)	—
Loss from continuing operations before benefit from income taxes	(374,000)	(380,000)
Benefit from income taxes	(36,000)	(16,000)
Loss from continuing operations	(338,000)	(364,000)
Income from discontinued operations, net of provision for income taxes of \$36,000 in 2013 and \$21,000 in 2012	—	16,000
Net loss	(338,000)	(348,000)
Other comprehensive income, net of tax		
Unrealized gain from marketable equity investments	148,000	—
Total other comprehensive income	148,000	—
Comprehensive loss	\$(190,000)	\$(348,000)
Per share data:		
Loss from continuing operations		
Basic	\$(0.10)	\$(0.11)
Diluted	\$(0.10)	\$(0.11)
Income from discontinued operations		
Basic	\$—	\$—
Diluted	\$—	\$—
Net loss		
Basic	\$(0.10)	\$(0.11)
Diluted	\$(0.10)	\$(0.11)
Weighted average shares outstanding - basic	3,343,499	3,319,180
Weighted average shares outstanding - diluted	3,343,499	3,319,180

See notes to unaudited condensed consolidated financial statements.

Table of Contents

PRO-DEX, INC. and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(unaudited)

	For the Six Months Ended December 31,	
	2013	2012
Net sales	\$5,194,000	\$6,468,000
Cost of sales	3,700,000	4,199,000
Gross profit	1,494,000	2,269,000
Operating expenses:		
Selling expenses	231,000	596,000
General and administrative expenses	878,000	1,234,000
Research and development costs	740,000	870,000
Total operating expenses	1,849,000	2,700,000
Loss from continuing operations before items below	(355,000)	(431,000)
Other expense (income):		
Interest expense	4,000	(6,000)
Interest income	(10,000)	—
Loss from disposal of equipment	6,000	—
Total other expense (income)	—	(6,000)
Loss from continuing operations before provision for income taxes	(355,000)	(437,000)
Benefit from income taxes	(35,000)	(19,000)
Loss from continuing operations	(320,000)	(418,000)
Income from discontinued operations, net of provision for income taxes of \$36,000 in 2013 and \$25,000 in 2012	194,000	53,000
Net loss	(126,000)	(365,000)
Other comprehensive income, net of tax		
Unrealized gain from marketable equity investments	204,000	—
Total other comprehensive income	204,000	—
Comprehensive income (loss)	\$78,000	\$(365,000)
Per share data:		
Loss from continuing operations		
Basic	\$(0.10)	\$(0.13)
Diluted	\$(0.10)	\$(0.13)
Income from discontinued operations		
Basic	\$0.06	\$0.02
Diluted	\$0.06	\$0.02
Net loss		
Basic	\$(0.04)	\$(0.11)
Diluted	\$(0.04)	\$(0.11)
Weighted average shares outstanding - basic	3,344,098	3,299,379
Weighted average shares outstanding - diluted	3,344,098	3,299,379

See notes to unaudited condensed consolidated financial statements.

Table of Contents

PRO-DEX, INC. and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**(unaudited)**

	For the Six Months Ended December 31,	
	2013	2012
Cash flows from operating activities:		
Net loss	\$ (126,000) \$ (365,000
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	283,000	298,000
Gain on sale of real estate held for sale	(167,000)
Allowance for doubtful accounts	7,000	(3,000
Share-based compensation	31,000	65,000
Changes in:		
Accounts receivable and other current receivables	(259,000) 440,000
Unbilled receivables	(367,000)
Inventories	282,000	(724,000
Prepaid expenses and other assets	(8,000) (65,000
Accounts payable, accrued expenses and deferred rent	(422,000) (512,000
Deferred revenue	106,000	36,000
Income taxes receivable and payable	(6,000) 39,000
Net cash used in operating activities	(646,000) (791,000
Cash flows from investing activities:		
Purchase of investments	(329,000)
Purchases of equipment	(15,000) (48,000
Proceeds from sale of real estate held for sale	900,000	—
Proceeds from sale of equipment	6,000	—
Increase in intangibles	(40,000)
Net cash provided by (used in) investing activities	522,000	(48,000
Cash flows from financing activities:		
Proceeds from exercise of stock options	—	50,000
Principal payments on capital lease and bank term loan	(2,000) (774,000
Net cash used in financing activities	(2,000) (724,000
Net decrease in cash	(126,000) (1,563,000
Cash, beginning of period	1,680,000	4,112,000
Cash, end of period	\$ 1,554,000	\$ 2,549,000
Supplemental Information		
Cash payments for interest	\$ 4,000	\$ 9,000
Cash payments for income taxes	\$ 7,000	\$ 5,000

See notes to unaudited condensed consolidated financial statements.

Table of Contents**PRO-DEX, INC. and SUBSIDIARIES****NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****NOTE 1. BASIS OF PRESENTATION**

The accompanying unaudited condensed consolidated financial statements of Pro-Dex, Inc. (“we”, “us”, “our”, “Pro-Dex” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-K. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the consolidated financial statements presented in our Annual Report on Form 10-K for the fiscal year ended June 30, 2013. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. The results of operations for such interim periods are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended June 30, 2013.

Recent Accounting Standards

In August 2013, the FASB issued ASU No. 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists,” that sets forth circumstances in which an unrecognized tax benefit, generally reflecting the difference between a tax position taken or expected to be taken on a company’s income tax return and the benefit recognized on its financial statements, should be presented in the company’s financial statements as a liability rather than as a reduction of a deferred tax asset. The ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013, with early adoption permitted. The adoption of these provisions is not expected to have a material impact on the consolidated financial statements of the Company.

NOTE 2. COMPOSITION OF CERTAIN FINANCIAL STATEMENT ITEMS**Inventories**

Inventories are stated at the lower of cost (first-in, first-out) or market and consist of the following:

	December 31, 2013	June 30, 2013
Raw materials / purchased components	\$ 1,538,000	\$ 1,640,000
Work in process	499,000	572,000
Sub-assemblies / Finished components	1,139,000	1,291,000
Finished goods	376,000	331,000
Total inventories	\$ 3,552,000	\$ 3,834,000

Investments

	December 31, 2013	June 30, 2013
Marketable equity securities	\$ 903,000	\$ 370,000

Investments at December 31, 2013 and June 30, 2013 had an aggregate cost basis of \$694,000 and \$365,000, respectively, gross unrealized gains aggregating \$209,000 and \$5,000, respectively, and no unrealized losses.

NOTE 3. WARRANTY

The warranty accrual is based on historical costs of warranty repairs and expected future identifiable warranty expenses, and is included in accrued expenses in the accompanying consolidated balance sheets. As of December 31, 2013 and June 30, 2013, the warranty reserve related to continuing operations amounted to \$200,000 and \$321,000, respectively. Warranty expenses are included in cost of sales in the accompanying consolidated statements of operations. Changes in estimates to previously established warranty accruals result from current period updates to assumptions regarding repair costs and warranty return rates, and are included in current period warranty expense. Total warranty expense for the three months ended December 31, 2013 and 2012 was \$16,000 and \$22,000, respectively, and for the six months ended December 31, 2013 and 2012 was \$29,000 and \$130,000, respectively.

Table of Contents

Information regarding the accrual for warranty costs for the three and six months ended December 31, 2013 and 2012 are as follows:

	Three Months Ended December 31,	
	2013	2012
Balances, beginning of period	\$229,000	\$585,000
Accruals during the period	47,000	38,000
Changes in estimates of prior period accruals	(31,000)	(16,000)
Warranty expenditures	(45,000)	(246,000)
Balances, end of period	\$200,000	\$361,000

	Six Months Ended December 31,	
	2013	2012
Balances, beginning of period	\$321,000	\$526,000
Accruals during the period	96,000	186,000
Changes in estimates of prior period accruals	(67,000)	(56,000)
Warranty expenditures	(150,000)	(295,000)
Balances, end of period	\$200,000	\$361,000

In 2013, we reclassified certain amounts, previously classified as warranty expenditures, to a classification as out-of-warranty repair expenditures, which reclassification had an offsetting effect on the changes in estimates of prior period accruals. The 2012 amounts appearing in the tables above have been reclassified to conform to the 2013 presentation. Such reclassifications had no effect on the accompanying condensed consolidated balance sheets or statements of operations.

NOTE 4. NET INCOME (LOSS) PER SHARE

The difference in the weighted average shares outstanding used in the calculation of basic and diluted net income (loss) per share for the three and six months ended December 31, 2013 and 2012 is as follows:

	Three Months Ended December 31,	
	2013	2012
Numerators for basic and diluted per share data:		
Loss from continuing operations	\$(338,000)	\$(364,000)
Income from discontinued operations	—	16,000

Edgar Filing: PRO DEX INC - Form 10-Q

Net loss			\$ (338,000)	\$ (348,000)
Denominators for basic and diluted per share data:				
Basic:				
Weighted average common shares outstanding			3,343,499	3,319,180
Shares used in the computation of basic per share data			3,343,499	3,319,180
Diluted:				
Shares used in the computation of basic per share data			3,343,499	3,319,180
Net shares assumed issued using the treasury stock method for outstanding common stock options			—	—
Shares used in the computation of diluted per share data			3,343,499	3,319,180
Basic and diluted per share data:				
Loss from continuing operations				
Basic			\$ (0.10)	\$ (0.11)
Diluted			\$ (0.10)	\$ (0.11)
Income from discontinued operations				
Basic			\$ —	\$ —
Diluted			\$ —	\$ —
Net loss				
Basic			\$ (0.10)	\$ (0.11)
Diluted			\$ (0.10)	\$ (0.11)

Table of Contents

	Six Months Ended December 31,	
	2013	2012
Numerators for basic and diluted per share data:		
Loss from continuing operations	\$(320,000)	\$(418,000)
Income from discontinued operations	194,000	53,000
Net loss	\$(126,000)	\$(365,000)
Denominators for basic and diluted per share data:		
Basic:		
Weighted average common shares outstanding	3,344,098	3,299,379
Shares used in the computation of basic per share data	3,344,098	3,299,379
Diluted:		
Shares used in the computation of basic per share data	3,344,098	3,299,379
Net shares assumed issued using the treasury stock method for outstanding common stock options	0	0
Shares used in the computation of diluted per share data	3,344,098	3,299,379
Basic and diluted per share data:		
Loss from continuing operations		
Basic	\$(0.10)	\$(0.13)
Diluted	\$(0.10)	\$(0.13)
Income from discontinued operations		
Basic	\$0.06	\$0.02
Diluted	\$0.06	\$0.02
Net loss		
Basic	\$(0.04)	\$(0.11)
Diluted	\$(0.04)	\$(0.11)
All outstanding options to purchase shares of our common stock, as described in Note 9, are not included in the calculation of diluted loss per share due to their anti-dilutive effect.		

NOTE 5. BANK DEBT

In February 2011, we entered into a credit facility agreement with Union Bank, N.A. that provided for the following:

- A revolving credit line of up to \$1.5 million in borrowing availability, under which no amounts were borrowed;
- A non-revolving credit line of up to \$350,000 in borrowing availability for the purchase of equipment, which expired unused on February 4, 2012; and
- A term loan of \$1.25 million, the outstanding balance of which, amounting to \$685,000, was repaid in full on September 24, 2012, as discussed further below.

On August 30, 2012, we notified the bank of our intent to terminate the credit facility agreements and on September 24, 2012, we repaid the entire principal balance of the term loan, amounting to \$685,000, and the credit facility agreements were terminated.

As a result of the foregoing, we no longer have a credit facility with a financial institution.

NOTE 6. DISCONTINUED OPERATIONS AND REAL ESTATE HELD FOR SALE

In February 2012, we completed the sale of our fractional horsepower motor product line, operating under the name Pro-Dex Astromec (“Astromec”) and located in Carson City, Nevada, to SL Montevideo Technology, Inc. (“MTI”), a wholly owned subsidiary of SL Industries, Inc., pursuant to an Asset Purchase Agreement (the “APA”).

Under the terms of the APA, we may receive earnout payments based on revenues generated from the sale of (i) Astromec products and (ii) MTI products to Astromec prospects (defined in the APA) (collectively, the “Earnout Sales Base”). Such earnout payments, if and when earned, are paid by MTI to us within 30 days following the end of each of our fiscal quarters during the three years subsequent to the February 2012 closing date, and amount to 6%, 4% and 2% of the Earnout Sales Base in the first, second and third such years, respectively. The earnout payments are recognized in the quarter in which we become entitled to receive them. We recognized income from earnout payments of \$41,000 and \$45,000 for the three months ended December 31, 2013 and 2012, respectively, and \$70,000 and \$92,000 for the six months ended December 31, 2013 and 2012, respectively. We have recognized an aggregate of \$301,000 in income from such earnout payments since the February 2012 closing date.

Table of Contents

In addition, as a result of the sale of the Astromec product line, we listed for sale the land and building constituting the facility in Carson City, Nevada, which was presented as real estate held for sale in the June 30, 2013 consolidated balance sheet with an aggregate carrying amount of \$733,000. On April 22, 2013, we entered into a Purchase Agreement with Aesthetic and Reconstructive Technologies, Inc., a Nevada corporation, whereby we agreed to sell the Carson City facility described above. On July 5, 2013, we completed the sale and closed the Purchase Agreement in conformity with its terms. The sales price of the property was \$980,000, of which we received net proceeds of \$900,000, after deductions for expenses related to the sale, primarily consisting of broker commissions and fees, aggregating approximately \$80,000, resulting in a gain of \$167,000.

Based on the foregoing, and in conformity with applicable accounting guidance, the Astromec product line qualifies as a discontinued operation. Accordingly, financial results of Astromec have been reported as discontinued operations in the accompanying consolidated statements of operations for all periods presented. Information regarding revenue and operating results of Astromec included in discontinued operations is as follows:

	Three Months Ended December 31,	
	2013	2012
Revenues	\$41,000	\$45,000
Income before provision for income taxes	\$36,000	\$37,000

	Six Months Ended December 31,	
	2013	2012
Revenues	\$70,000	\$92,000
Income before provision for income taxes	\$230,000	\$78,000

Information regarding Astromec assets and liabilities included in the accompanying consolidated balance sheets is as follows:

	December 31, 2013	June 30, 2013
Accounts receivable	\$ 41,000	\$31,000
Accrued expenses	\$ 2,000	\$5,000

NOTE 7. INCOME TAXES

Deferred income taxes are provided on a liability method whereby deferred tax assets and liabilities are recognized for temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Significant management judgment is required in determining our provision for income taxes and the recoverability of our deferred tax assets. Such determination is based primarily on our historical taxable income or loss, with some

consideration given to our estimates of future taxable income or loss by jurisdictions in which we operate and the period over which our deferred tax assets would be recoverable. Due to cumulative taxable losses during the past three years, we maintained a valuation allowance of \$3.4 million against our deferred tax assets as of June 30, 2013.

As of December 31, 2013, we have accrued \$364,000 of unrecognized tax benefits related to federal and state income tax matters. The amount that would reduce the Company's income tax expense if recognized and result in a corresponding decrease in the Company's effective tax rate is \$47,000.

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

Balance at July 1, 2013	\$ 347,000
Additions based on tax positions related to the current year	17,000
Additions for tax positions of prior years	
Reductions for tax positions of prior years	
Balance at December 31, 2013	\$ 364,000

We recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense when applicable. As of December 31, 2013, no interest or penalties applicable to our unrecognized tax benefits have been accrued since we have sufficient tax attributes available to fully offset any potential assessment of additional tax.

Pro-Dex and its subsidiaries are subject to U.S. federal income tax, as well as income tax of multiple state tax jurisdictions. We are currently open to audit under the statute of limitations by the Internal Revenue Service for the years ended June 30, 2011 and later. Our state income tax returns are open to audit under the statute of limitations for the years ended June 30, 2010 and later. We do not anticipate a significant change to the total amount of unrecognized tax benefits within the next 12 months.

Table of Contents

NOTE 8. COMMON STOCK

Rights Offering

On December 17, 2013, we publicly announced plans to complete a rights offering to existing holders of our Common Stock and filed a preliminary Form S-3 with the Securities and Exchange Commission. Upon completion of the rights offering, we expect to receive gross proceeds of approximately \$3,000,000 before expenses, subject to reduction by us in our sole discretion as we may deem advisable to preserve our use of tax attributes such as net operating loss carryforwards or for other reasons. We have received a standby commitment from AO Partners, LLC and Farnam Street Capital, Inc. (each a beneficial shareholder of our common stock; each a “Standby Purchaser” and collectively the “Standby Purchasers”) to purchase any and all shares of Common Stock that are not subscribed for by shareholders in connection with the rights offering, subject to reduction by us as described above. Nicholas J. Swenson, one of our directors, is the Managing Member of AO Partners and, in such capacity, has the power to direct the affairs of AO Partners. Raymond E. Cabillot, also one of our directors, is Chief Executive Officer and a director of Farnam Street Capital and, in such capacity, has the power to direct the affairs of Farnam Street Capital. No fees or other consideration will be paid by us to the Standby Purchasers in exchange for their commitment to purchase any and all unsubscribed shares of Common Stock following the rights offering.

The rights offering will be made through a distribution to our existing shareholders of non-transferable subscription rights to purchase their pro rata portion of newly issued shares of Common Stock. The subscription price has not yet been determined but is expected to be based on a percentage discount of the closing market price of the Common Stock, as reported by the NASDAQ Capital Market, on the latest practicable date prior to the launch of the rights offering. The record date for the distribution of the rights and the dates for both the subscription period and the expiration of the rights offering will be included in the final prospectus that will be filed with the Securities and Exchange Commission (“SEC”).

We intend to use the net proceeds from the Rights Offering to pursue strategic opportunities that may present themselves from time to time or, if not used to pursue strategic opportunities, for working capital and general corporate purposes, including to fund ongoing research and development and product initiatives. Also, to the extent net proceeds of the Rights Offering are not deployed, some of the funds may be invested in accordance with the terms of our Surplus Capital Investment Policy.

Share Repurchase Program

In September 2013, our Board approved a share repurchase program authorizing the Company, at the direction of the Investment Committee of the Board, to repurchase up to 750,000 shares of our common stock under parameters to be determined by the Investment Committee. The repurchase program has no stated expiration date and there have been no purchases under the program.

NOTE 9. SHARE-BASED COMPENSATION

We have two equity compensation plans, the Second Amended and Restated 2004 Stock Option Plan (the “Employees Stock Option Plan”) and the Amended and Restated 2004 Directors Stock Option Plan (the “Directors Stock Option Plan”) (collectively, the “Stock Option Plans”), pursuant to which (i) options to purchase shares of common stock, or (ii) restricted shares of common stock, may be granted up to an aggregate amount of 1,333,333 common shares, with 1,066,667 and 266,666 shares distributed between the Employees Stock Option Plan and the Directors Stock Option Plan, respectively. The Stock Option Plans are substantially similar, providing for a strike price equal to the closing price for a share of our common stock as of the last business day immediately prior to the grant date, vesting periods as determined by the Board for the Employees Stock Option Plan and six months for the Directors Stock Option Plan, and terms of up to ten years, subject to forfeit 30 days after the holder ceases to be an employee or 90 days after the holder ceases to be director, as the case may be. At December 31, 2013, 506,105 and 173,334 shares under the Employees Stock Option Plan and the Directors Stock Option Plan, respectively, are available to grant in future years. Share-based compensation expense under the Stock Option Plans for the three months ended December 31, 2013 and 2012 was \$12,000 and \$36,000, respectively, and for the six months ended December 31, 2013 and 2012 was \$31,000 and \$65,000, respectively.

Stock Options

The following assumptions were used in the calculation of share-based compensation expense for options granted during the three and six months ended December 31, 2012:

Dividend rate	None
Price volatility	87%
Risk-free interest rate	0.9%
Expected life	6.0 years

No options were granted during the three or six months ended December 31, 2013.

Table of Contents

As of December 31, 2013, there was an aggregate of \$34,000 of unrecognized compensation cost under the Stock Option Plans related to 43,000 non-vested outstanding stock options with a per share weighted average value of \$1.80. The unrecognized expense is anticipated to be recognized on a straight-line basis over a weighted average period of 1.4 years. Following is a summary of stock option activity for the six months ended December 31, 2013 and 2012:

	2013		2012	
	Shares	Weighted-Average Exercise Price	Shares	Weighted-Average Exercise Price
Outstanding at beginning of period	292,504	\$ 2.35	591,672	\$ 2.48
Granted	—	—	35,000	1.73
Exercised	(804)	1.80	(33,334)	1.50
Forfeited	(100,306)	2.34	(13,334)	7.74
Outstanding at end of period	191,394	\$ 2.36	580,004	\$ 2.37
Exercisable at end of period	148,061	\$ 2.53	250,976	\$ 2.96
Weighted-average fair value per option granted during the period		\$ —		\$ 1.25

Following is a summary of information regarding options outstanding and options exercisable at December 31, 2013:

Range of Exercise Price	Number Outstanding	Options Outstanding			Options Exercisable			
		Average Contractual Life	Average Exercise Price	Aggregate Intrinsic Value	Number Outstanding	Average Contractual Life Remaining	Average Exercise Price	Aggregate Intrinsic Value
\$0 to \$2.50....	169,725	7.86	\$ 1.87	\$ 95,546	126,392	7.68	\$ 1.89	\$ 67,971
\$2.51 to \$5.00....	3,334	3.38	4.38	—	3,334	3.38	4.38	—
\$5.01 to \$7.50....	10,001	0.49	5.61	—	10,001	0.49	5.61	—
\$7.51 to \$10.00....	8,334	2.02	7.65	—	8,334	2.02	7.65	—
Total	191,394	7.14	\$ 2.36	\$ 95,546	148,061	6.78	\$ 2.53	\$ 67,971

Restricted Stock

The following is a summary of restricted share activity for the six months ended December 31, 2013 and 2012:

2013		2012	
Shares	Weighted-Average Grant	Shares	Weighted-Average Grant

Edgar Filing: PRO DEX INC - Form 10-Q

		Date		Date
		Fair Value		Fair Value
Outstanding at beginning of year	32,500	\$ 1.73	—	
Granted	—	—	35,000	\$ 1.73
Vested	(9,166)	1.73	—	—
Forfeited	(6,667)	1.73	(2,500)	1.73
Outstanding at end of period	16,667	\$ 1.73	32,500	\$ 1.73

As of December 31, 2013, there was \$19,000 in unrecognized compensation cost related to non-vested outstanding restricted shares. The unrecognized expense is anticipated to be amortized over the next 1.7 years.

Table of Contents

NOTE 10. MAJOR CUSTOMERS

Information with respect to two customers who accounted for sales in excess of 10% of our total sales in either of the three-month periods or either of the six-month periods ended December 31, 2013 or 2012 is as follows:

	As of and for the three months ended December 31,				2012				
	2013	Sales	Percent of Total	Accounts Receivable	Percent of Total	Sales	Percent of Total	Accounts Receivable	Percent of Total
Customer 1	\$ 1,296,000	49 %	\$ 841,000	53 %	\$ 1,136,000	38 %	\$ 432,000	32 %	
Customer 2	\$ 97,000	4 %	\$ 9,000	1 %	\$ 372,000	12 %	\$ 124,000	11 %	

	As of and for the six months ended December 31,				2012				
	2013	Sales	Percent of Total	Accounts Receivable	Percent of Total	Sales	Percent of Total	Accounts Receivable	Percent of Total
Customer 1	\$ 2,393,000	46 %	\$ 841,000	53 %	\$ 3,072,000	47 %	\$ 432,000	32 %	

NOTE 11. COMMITMENTS AND CONTINGENCIES

Change of Control Agreements

We have Change of Control Agreements with our Chief Executive Officer and Chief Financial Officer, Harold A. Hurwitz, and our Chief Operating Officer, Richard L. Van Kirk. The Change of Control Agreements provide that, if the individual's employment with us involuntarily terminates (as such term is defined in the Change of Control Agreements) within 12 months after a change of control (also as such term is defined in the Change of Control Agreements), the individual will receive, subject to signing a release of claims, (i) a lump sum amount equal to 30 weeks base compensation of the individual at the time of such termination and (ii) 100% Company-paid insurance coverage as provided to the individual immediately prior to his termination of employment for a period equal to the earlier of (i) 12 months following termination or (ii) until the individual becomes covered under another employer's insurance plan. In addition, the individual shall be entitled to receive bonus or compensation award payments, if any, in accordance with the terms of our incentive compensation plans in which the individual was an eligible participant at the time of the termination. No changes of control have taken place that would result in the potential payment of benefits under the terms of the Change of Control Agreements as described herein. The Change of Control Agreements expire in July 2014.

Legal Matters

In February 2011, we became aware of a report entitled "Site Discovery Report, Southeast Santa Ana Project DTSC – Cypress Region," dated February 2010 (the "Report"), that was prepared by the Cypress regional office of the Cal/EPA Department of Toxic Substances Control ("DTSC") for Region 9 of the U.S. Environmental Protection Agency ("USEPA") under an agreement between the two agencies. The purpose of the Report was to identify sites within an area of southeast Santa Ana, California that may be sources of groundwater contamination previously detected in that area. The Report identified 25 sites, including our former Santa Ana site, for further screening by DTSC staff. DTSC

has informed us that no further evaluation of our former site has taken place subsequent to the Report's issuance. It is uncertain whether future developments, if any, from DTSC's screening process would have any application to our former site.

In general, we are from time to time a party to various legal proceedings incidental to our business, none of which we consider may be material. There can be no certainty, however, that we may not ultimately incur liability or that such liability will not be material and adverse.

NOTE 12. FAIR VALUE MEASUREMENTS

Fair value is measured based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Table of Contents

Cash and cash equivalents: The carrying value of cash and cash equivalents is considered to be representative of their fair values based on the short term nature of these instruments. As such, cash and cash equivalents are classified within Level 1 of the valuation hierarchy.

Investments: Investments consist of marketable equity securities of publicly held companies. As such, investments are classified within Level 1 of the valuation hierarchy.

Although the methods above may produce a fair value calculation that may not be indicative of the net realizable value or reflective of future fair values, we believe its valuation methods are appropriate.

NOTE 13. SUBSEQUENT EVENTS

We have evaluated events or transactions that occurred after the balance sheet date of December 31, 2013 and have identified no such events or transactions which required adjustment to, or disclosure in, these Condensed Consolidated Financial Statements other than as presented in such financial statements and the Notes thereto.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

COMPANY OVERVIEW

The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of the results of operations and financial condition of Pro-Dex, Inc. ("Company", "Pro-Dex", "we", "our" or "us") for the three and six-month periods ended December 31, 2013 and 2012. This discussion should be read in conjunction with the Condensed Consolidated Financial Statements and the Notes thereto included elsewhere in this report. This report contains certain forward-looking statements and information. The cautionary statements included herein should be read as being applicable to all related forward-looking statements wherever they may appear. Our actual future results could differ materially from those discussed herein.

Except for the historical information contained herein, the matters discussed in this report, including, but not limited to, discussions of our product development plans, business strategies, strategic opportunities and market factors influencing our results, are forward-looking statements that involve certain risks and uncertainties. Actual results may differ from those anticipated by us as a result of various factors, both foreseen and unforeseen, including, but not limited to, our ability to continue to develop new products and increase sales in markets characterized by rapid technological evolution, consolidation within our target marketplace and among our competitors, competition from larger, better capitalized competitors, and our ability to realize returns on opportunities. Many other economic, competitive, governmental and technological factors could impact our ability to achieve our goals. You are urged to review the risks, uncertainties and other cautionary language described in this report, as well as in our other public disclosures and reports filed with the Securities and Exchange Commission ("SEC") from time to time, including, but not limited to, the risks, uncertainties and other cautionary language discussed in our Annual Report on Form 10-K for our fiscal year ended June 30, 2013.

With operations in Irvine, California and Beaverton, Oregon, we provide products used in medical, research and industrial applications. Experience in surgical devices and multi-axis motion control applications allows us to develop products that require high precision in harsh environments.

Our products are found in hospitals, dental offices, medical engineering labs, scientific research facilities and high tech manufacturing operations around the world. The names Micro Motors and Oregon Micro Systems are used for marketing purposes as brand names.

Our principal headquarters are located at 2361 McGaw Avenue, Irvine, California 92614 and our phone number is (949) 769-3200. Our Internet address is www.pro-dex.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, amendments to those reports and other SEC filings, are available free of charge through our website as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC. In addition, our Code of Ethics and other corporate governance documents may be found on our website at the Internet address set forth above. Our filings with the SEC may also be read and copied at the SEC's Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov and company specific information at www.sec.gov/edgar/searchedgar/companysearch.html.

Critical Accounting Estimates and Judgments

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of our financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. We base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

Revenue Recognition

Revenue on product sales is recognized upon shipment to the customer when risk of loss and title transfer to the customer and all other conditions required by GAAP, as promulgated by the Financial Accounting Standards Board (“FASB”) in Accounting Standards Codification (“ASC”) Section 605 (formerly Staff Accounting Bulletin No. 104, *Revenue Recognition*), have been satisfied.

Revenue from billable product development service portions of development and supply contracts is generally recognized upon completion of such product development services, in conformity with ASC Section 605. Anticipated losses on product development services are charged to cost of sales in the period in which such losses become probable.

Returns of our product for credit are minimal; accordingly, we do not establish a reserve for product returns at the time of sale.

Warranties

Certain of our products are sold with a warranty that provides for repairs or replacement of any defective parts for a period, generally one or two years, after the sale. At the time of the sale, we accrue an estimate of the cost of providing the warranty based on prior experience with factors such as return rates and repair costs, which factors are reviewed quarterly.

Warranty expenses, including changes of estimates, are included in cost of sales in our consolidated statements of operations.

Table of Contents

Inventories

Inventories are stated at the lower of cost (first-in, first-out) or market value. Reductions to estimated market value are recorded, and charged to cost of sales, when indicated based on a formula that compares on-hand quantities to estimated demand over the ensuing 12 months from the measurement date.

Accounts Receivable and Unbilled Receivables

Trade receivables are stated at their original invoice amounts, less an allowance for doubtful accounts. Management determines the allowance for doubtful accounts based on facts and circumstances related to specific accounts, and on historical experience related to the age of accounts. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously reserved are offset against the allowance when received.

Unbilled receivables reflect revenues from non-recurring engineering services not yet billable to customers under the terms of the related development and supply contracts.

Investments

Investments consist of marketable equity securities of publicly held companies. Management intends to hold such securities for a sufficient period in which to realize a reasonable return, although there is no assurance that positive returns will be realized or that such securities will not be liquidated in a shorter-than-expected time frame to accommodate our liquidity requirements. Accordingly, investments have been classified as non-current and available-for-sale in conformity with ASC Section 320. Investments are marked to market at each measurement date, with unrealized gains and losses presented as adjustments to accumulated other comprehensive income or loss.

Equipment and leasehold improvements

We review the recoverability of equipment and leasehold improvements when events or changes in circumstances occur that indicate carrying values may not be recoverable.

Intangibles

Intangibles consist of legal fees incurred in connection with patent applications, and will be amortized over the life of the applicable patent upon its issuance.

Stock-Based Compensation

We recognize compensation expense for all share-based awards made to employees and directors by estimating the fair value of share-based awards at the grant date and recognizing compensation expense over the requisite service period.

For stock options, fair value is estimated using the Black-Scholes option-pricing model. The portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period using the straight-line single option method.

The determination of fair value using the Black-Scholes model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected stock option exercise behavior. We currently estimate stock price volatility based upon historical activity, with future volatility expected to approximate past volatility. The expected time to exercise is based on a simplified model of the vesting term of the option plus one-half the option life.

Income Taxes

We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities along with net operating loss and tax credit carryovers. Deferred tax assets at December 31, 2013 and June 30, 2013 consisted primarily of basis differences related to research and development tax credit utilization, net operating loss carryovers, intangible assets, accrued expenses and inventories.

Significant management judgment is required in determining our provision for income taxes and the recoverability of our deferred tax assets. Such determination is based on our historical taxable income or loss, with consideration given to our estimates of future taxable income or loss and the periods over which deferred tax assets will be recoverable. We record a valuation allowance against deferred tax assets to reduce the net carrying value to an amount that we believe is more likely than not to be realized. When we establish or reduce the valuation allowance against deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. At December 31, 2013 and June 30, 2013, we maintained a valuation allowance against the entire balance of our deferred tax assets, net of deferred tax liabilities.

Table of Contents

Description of Business

The majority of our revenue is derived from designing, developing and manufacturing surgical devices for the medical device and dental industries and motion control software and hardware for industrial and scientific applications. The proportion of total sales by customer type is as follows:

	Three Months Ended December				Six Months Ended December			
	30, 2013		2012		30, 2013		2012	
	(Dollars in thousands)							
<u>Customer type</u>								
Medical device development and manufacturing	\$1,690	64 %	\$2,118	70 %	\$3,389	65 %	\$4,574	71 %
Industrial	497	19 %	585	19 %	1,017	20 %	1,350	21 %
Dental	443	17 %	291	10 %	767	15 %	521	8 %
Government and other	10	— %	13	—	21	—	23	— %
Total sales	\$2,640	100%	\$3,007	100%	\$5,194	100%	\$6,468	100

Certain of our medical device products utilize proprietary designs developed by us under exclusive development and supply agreements. All of our medical device products utilize proprietary manufacturing methods and know-how, and are manufactured in our Irvine, California facility, as are our dental products, which are sold primarily to original equipment manufacturers and dental product distributors. We design and manufacture embedded multi-axis motion controllers in our facility in Beaverton, Oregon.

At December 31, 2013, we had a backlog of \$5.0 million. We may experience variability in our new order bookings due to various reasons, including, but not limited to, the timing of major new product launches and customer planned inventory builds. However, we do not typically experience seasonal fluctuations in our shipments and revenues.

RESULTS OF OPERATIONS

Comparison of the three months ended December 31, 2013 and 2012

The following table sets forth financial data and the percentage of net sales of our operating results:

	Three Months Ended December			
	31, 2013		2012	
	Dollars in thousands			
Net sales	\$2,640	100%	\$3,007	100%
Cost of sales	2,091	79 %	1,974	66 %
Gross profit	549	21 %	1,033	34 %
Selling expenses	139	5 %	322	11 %
General and administrative expenses	422	16 %	627	21 %
Research and development costs	364	14 %	464	15 %

Edgar Filing: PRO DEX INC - Form 10-Q

Loss from continuing operations before items below	(376)	(14)%	(380)	-13 %
Interest (income) expense and other, net	(2)	0 %	0	0 %
Loss from continuing operations before benefit from income taxes	(374)	(14)%	(380)	-13 %
Benefit from income taxes	(36)	(1)%	(16)	-1 %
Loss from continuing operations	(338)	(13)%	(364)	-12 %
Income from discontinued operations	—	— %	16	1 %
Net loss	\$(338)	(13)%	\$(348)	-11 %

Net sales for the three months ended December 31, 2013 decreased \$367,000, or 12%, to \$2.6 million from \$3.0 million for the three months ended December 31, 2012 due primarily to decreases of \$428,000 in medical device development and manufacturing revenues, and \$48,000 in motion control product revenues, which were partially offset by an increase of \$152,000 in dental product revenues.

Contributing to the \$428,000 decrease related to our medical device product line was a \$275,000 decrease in repair revenues from our former largest customer, which was partially offset by an increase of \$161,000 in product and repair revenues from our current largest customer. Pursuant to an agreement with our former customer, which commits the customer to a minimum amount of inventory purchases at the agreement's termination in June 2014, we expect sales to the customer to continue to decline through the agreement's term, after which we expect no further revenues from this customer. The increase in sales to our current largest customer reflects the resumption of orders from that customer, which had been curtailed since March 2013. We expect to continue receiving such orders through December 2014, the termination date of the customer's current purchase commitment. Negotiations for future arrangements with this customer have not yet commenced. Medical device sales to other customers decreased \$181,000 and medical device design revenues decreased \$133,000.

Table of Contents

Gross profit for the three months ended December 31, 2013 decreased \$484,000, or 47%, to \$549,000 from \$1.0 million for the same period in 2012. Contributing to this decrease were the reduction in sales volume, described above, and the effects of unfavorable changes in the mix of product sales, which reduced gross profit by \$126,000 and \$139,000, respectively. Also contributing to the decrease in gross profit was an increase of \$199,000 in the accrual for anticipated losses from the development services portion of certain contracts, and an increase of \$166,000 in unfavorable production variances related to reduced manufacturing volumes, which were partially offset by a decrease of \$60,000 in warranty expense. The factors affecting gross profit described above, other than the reduction in sales volume, also resulted in a decrease of gross margin as a percentage of sales to 21% for the three months ended December 31, 2013 from 34% for the corresponding period in 2012.

Selling expenses decreased \$183,000, or 57%, to \$139,000 for the three months ended December 31, 2013, from \$322,000 for the corresponding period in 2012. This decrease is attributable primarily to decreases in employee compensation costs of \$129,000, advertising expenses of \$5,000 and in travel and tradeshow expenses of \$35,000.

General and administrative expenses decreased \$205,000, or 33%, to \$422,000 for the three months ended December 31, 2013, from \$627,000 for the corresponding period in 2012, due primarily to decreases in legal expense of \$83,000 and external reporting expenses of \$33,000 (of which \$40,000 in legal and external reporting expenses incurred in 2012 related to non-recurring proxy contest costs), employee compensation expenses of \$48,000 and stock option expense of \$23,000.

Research and development costs, which include costs related to development of new products and enhancements to existing products, decreased by \$100,000, or 22%, to \$364,000 for the three months ended December 31, 2013, from \$464,000 for the three months ended December 31, 2012 due primarily to the utilization of engineering resources in contractual revenue-producing activities of \$84,000 and a decrease in small motor development expense of \$53,000, offset by increased employee compensation expense of \$59,000.

The effective tax rates for the three-month periods ended December 31, 2013 and 2012 were lower than statutory tax rates due to our inability to fully recognize the benefits of federal and state loss carryforwards prior to their utilization. (See Note 7 of Notes to Condensed Consolidated Financial Statements contained elsewhere in this report.)

As a result of the foregoing, loss from continuing operations for the three months ended December 31, 2013 was \$338,000, as compared to a loss of \$364,000 for the three months ended December 31, 2012.

Comparison of the six months ended December 31, 2013 and 2012

The following table sets forth financial data and the percentage of net sales of our operating results:

	Six Months Ended December 31,			
	2013		2012	
	Dollars in thousands			
Net sales	\$5,194	100 %	\$6,468	100 %
Cost of sales	3,700	71 %	4,199	65 %
Gross profit	1,494	29 %	2,269	35 %
Selling expenses	231	4 %	596	9 %
General and administrative expenses	878	17 %	1,234	19 %

Edgar Filing: PRO DEX INC - Form 10-Q

Research and development costs	740	14 %	870	13 %
Loss from continuing operations before items below	(355)	(6)%	(431)	-6 %
Interest (income) expense and other, net	—	— %	6	0 %
Loss before provision for (benefit from) income taxes	(355)	(6)%	(437)	-6 %
Provision for (benefit from) income taxes	35	0 %	(19)	0 %
Loss from continuing operations	(320)	(6)%	(418)	-6 %
Income from discontinued operations	194	4 %	53	1 %
Net loss	\$(126)	(2)%	\$(365)	-5 %

Net sales for the six months ended December 31, 2013 decreased \$1.3 million, or 20%, to \$5.2 million from \$6.5 million for the six months ended December 31, 2012 due primarily to a decreases of \$1.2 million in medical device development and manufacturing revenues, and \$341,000 in motion control product revenues, which were partially offset by an increase of \$246,000 in dental product revenues.

The \$1.2 million decrease related to our medical device product line was comprised of a \$201,000 decrease in repair revenues from our former largest customer, and a \$679,000 decrease in revenues from our current largest customer. Pursuant to a repair agreement with our former customer, which commits the customer to a minimum amount of inventory purchases at the agreement's termination in June 2014, we expect sales to the customer to continue to decline through the agreement's term, after which we expect no further revenues from this customer. The decrease in sales to our current largest customer reflects the curtailment of orders from this customer since March 2013, with a resumption of orders from this customer commencing in December 2013. We expect to continue receiving such orders through December 2014, the termination date of the customer's current purchase commitment. Negotiations for future arrangements with this customer have not yet commenced. Also contributing to the decrease in medical device revenues was a \$130,000 decrease in product sales to other medical device customers, and a \$175,000 decrease in medical device design revenues.

Table of Contents

Gross profit for the six months ended December 31, 2013 decreased \$775,000, or 34%, to \$1.5 million from \$2.3 million for the same period in 2012. Contributing to this decrease were the reduction in sales volume described above and the effects of unfavorable changes in the mix of product sales, which reduced gross profit by \$493,000 and \$143,000, respectively. Also contributing to the decrease in gross profit was an increase of \$212,000 in the accrual for anticipated losses from the development services portion of certain contracts, and an increase of \$198,000 in unfavorable production variances related to reduced manufacturing volumes, which were partially offset by a decrease of \$213,000 in warranty expense resulting from lower sales volume in the 2013 period, relative to the 2012 period, and the warranty expiration in the 2013 period related to units sold in prior years. The factors affecting gross profit described above, other than the reduction in sales volume, also resulted in a decrease of gross margin as a percentage of sales to 29% for the six months ended December 31, 2013 from 35% for the corresponding period in 2012.

Selling expenses decreased \$365,000, or 61%, to \$231,000 for the six months ended December 31, 2013, from \$596,000 for the corresponding period in 2012. This decrease is attributable primarily to decreases in employee compensation costs of \$238,000, advertising expenses of \$46,000 and in travel and tradeshow expenses of \$50,000.

General and administrative expenses decreased \$356,000, or 29%, to \$878,000 for the six months ended December 31, 2013, from \$1,234,000 for the corresponding period in 2012, due primarily to decreases in legal expense of \$76,000 and external reporting expense of \$70,000 (of which \$41,000 in legal and external reporting expenses incurred in 2012 related to non-recurring proxy contest costs), employee compensation expense of \$125,000 and stock option expense of \$34,000.

Research and development costs, which include costs related to development of new products and enhancements to existing products, decreased by \$130,000, or 15%, to \$740,000 for the six months ended December 31, 2013, from \$870,000 for the six months ended December 31, 2012, due primarily to the utilization of engineering resources in contractual revenue-producing activities of \$163,000 and a decrease in small motor development expense of \$46,000, offset by increased employee compensation expense of \$112,000.

The effective tax rates for the six-month periods ended December 31, 2013 and 2012 were lower than statutory tax rates due to our inability to fully recognize the benefits of federal and state loss carryforwards prior to their utilization. (See Note 7 of Notes to Condensed Consolidated Financial Statements contained elsewhere in this report.)

As a result of the foregoing, loss from continuing operations for the six months ended December 31, 2013 was \$320,000, as compared to a loss of \$418,000 for the six months ended December 31, 2012.

Liquidity and Capital Resources

The following table presents selected financial information as of December 31, 2013 and June 30, 2013:

	December 31, 2013	June 30, 2013
Cash and cash equivalents	\$ 1,554,000	\$ 1,680,000
Working capital	\$ 5,558,000	\$ 5,033,000
Cash and cash equivalents, net of capital lease obligations	\$ 1,535,000	\$ 1,660,000

Net cash used in operating activities during the six months ended December 31, 2013 amounted to \$646,000. Uses of cash arose from (a) an increase in accounts receivable of \$259,000, primarily due to the resumption, in December 2013, of shipments to our largest customer, the payments for which were not received until January 2014 in conformity with our customary credit terms, (b) and increase of \$367,000 in unbilled receivables related to the

development phase of certain contracts that have not yet reached the billable stage under the completed contract method of accounting, and (c) a decrease in accounts payable, accrued liabilities and deferred rent, aggregating \$422,000, due primarily to payments made during the six months ended December 31, 2013 for inventory purchased during the quarter ended June 30, 2013. Sources of cash arose from (a) a reduction in inventories of \$282,000, reflecting primarily the resumption of shipments to our largest customer as discussed above, and (b) a \$106,000 increase in deferred revenue related to contractual payments made to us by customers in advance of our ability to recognize such payments as revenue.

Net cash used in operating activities during the six months ended December 31, 2012 amounted to \$791,000. Uses of cash arose primarily from (a) a build-up of inventory of \$724,000 related primarily to the purchase of components required to fulfill firm customer purchase orders in backlog as well as repair and warranty orders, and to build our stock of components related to certain of our products with the objective of shortening lead times when forecasted purchase orders are received, (b) a reduction from June 30, 2012 in accounts payable and accrued liabilities aggregating \$512,000, and (c) an increase of \$65,000 in prepaid expenses, primarily relating to annual insurance policy renewals in October 2012. Partially offsetting these cash uses were (a) a decrease in accounts receivable and other current receivables of \$440,000, due primarily to the lower sales volume, and (b) a reduction in income taxes receivable of \$39,000, representing a refund of taxes paid in the prior year.

Net cash provided by investing activities for the six months ended December 31, 2013 was \$522,000. This increase was due primarily to proceeds of \$900,000 from the sale of land and building we owned in Carson City, Nevada that housed our former Astromec operations, partially offset by additions of \$329,000 we made to our investments in marketable equity securities in conformity with our surplus capital investment policy (see "Surplus Capital Investment Policy" below). Net cash used in investing activities for the six months ended December 31, 2012 was \$48,000 and consisted of capital expenditures for manufacturing equipment.

Net cash used in financing activities for the six months ended December 31, 2013 was \$2,000 and represented payments on equipment capital leases. Net cash used in financing activities for the six months ended December 31, 2012 was \$724,000, and was due primarily to payments amounting to \$774,000, including our complete repayment in September 2012 of the remaining balance due, amounting to \$685,000, on the Union Bank term loan, fully retiring such indebtedness (see Note 5 of Notes to Condensed Consolidated Financial Statements contained elsewhere in this report and "Changes in Bank Debt and Credit Facilities" below). Partially offsetting such use of cash in financing activities were proceeds, amounting to \$50,000 in connection with the exercise of stock options.

Table of Contents

We believe that existing cash balances and cash flows from operations will be sufficient to fund operations for the next twelve months.

Changes in Bank Debt and Credit Facilities

As more fully described in Note 5 of Notes to Condensed Consolidated Financial Statements contained elsewhere in this report, in February 2011, we entered into a credit facility agreement with Union Bank that provided for (a) a revolving credit line of up to \$1.5 million, (b) a non-revolving credit line of up to \$350,000 for the purchase of equipment, and (c) a term loan of \$1.25 million.

On August 30, 2012, we notified the bank of our intent to terminate the credit facility agreements and on September 24, 2012, we repaid the entire principal balance of the term loan, amounting to \$685,000 and the credit facility agreements were terminated.

As a result of the foregoing, we no longer have a credit facility with a financial institution. Should we be unable to achieve anticipated cash flows from operations, we may be required to seek new financing. However, there is no assurance that such financing will be available on acceptable terms, if at all.

Reduction in Directors' Compensation

At our 2012 Annual Meeting held on January 17, 2013, our shareholders elected four new members to our Board of Directors. At a meeting of the newly constituted Board on February 4, 2013, three of those newly elected directors, Messrs. Swenson, Cabillot and Farrell, each opted to waive, through the date of our 2013 Annual Meeting of Shareholders, (a) receipt of stock options they were otherwise entitled to receive under the provisions of the directors' compensation plan then in effect (the "2010 Plan"), and (b) any cash retainers or meeting fees they were otherwise entitled to receive under the 2010 Plan in excess of \$200 per meeting and \$2,000 per year.

At its meeting on May 2, 2013, our Board replaced the 2010 Plan with the 2013 Directors' Compensation Plan (the "2013 Plan") that provides for the following:

- Fees of \$200 for participation in Board or Committee meetings, to a maximum of \$2,000 per fiscal year;
- An annual retainer of \$23,000 for the Audit Committee Chair (which may be modified in compensating any future Audit Committee Chair)

The 2013 Plan has no provision for (a) retainers other than that described above, or (b) grants of options to purchase shares of our common stock. (See Note 11 of Notes to Condensed Consolidated Financial Statements.)

Surplus Capital Investment Policy

At its April 17, 2013 meeting, our Board approved a Surplus Capital Investment Policy (the "Policy") that provides, among other items, for the following:

- (a) Determination by our Board of Directors of (i) our surplus capital balance and (ii) the portion of such surplus capital balance to be invested according to the Policy;
- (b) Selection of an Investment Committee responsible for implementing the Policy; and
- (c) Objectives and criteria under which investments may be made.

The composition of the Investment Committee is Messrs. Swenson (Chair) and Cabillot, both of whom are members of our Board of Directors, and Mr. Hurwitz, Chief Executive Officer and Chief Financial Officer.

In June 2013, the Investment Committee approved investments aggregating \$500,000, and approved an additional \$500,000 in July 2013. At December 31, 2013, \$694,000 had been invested in marketable public equity securities, having a market value at December 31, 2013 of \$903,000, and \$314,000 was invested in money market funds.

In September 2013, our Board approved a share repurchase program authorizing the Company, at the direction of the Investment Committee, to repurchase up to 750,000 shares of our common stock under parameters to be determined by the Investment Committee. The repurchase program has no stated expiration date and there have been no purchases under the program.

Rights Offering

On December 17, 2013, we publicly announced plans to complete a rights offering to existing holders of our Common Stock and filed a preliminary Form S-3 with the Securities and Exchange Commission. Upon completion of the rights offering, we expect to receive gross proceeds of approximately \$3,000,000 before expenses, subject to reduction by us in our sole discretion as we may deem advisable to preserve our use of tax attributes such as net operating loss carryforwards or for other reasons. We have received a standby commitment from AO Partners, LLC and Farnam Street Capital, Inc. (each a beneficial shareholder of our common stock; each a “Standby Purchaser” and collectively the “Standby Purchasers”) to purchase any and all shares of Common Stock that are not subscribed for by shareholders in connection with the rights offering, subject to reduction by us as described above. Mr. Swenson is the Managing Member of AO Partners and, in such capacity, has the power to direct the affairs of AO Partners. Mr. Cabillot is Chief Executive Officer and a director of Farnam Street Capital and, in such capacity, has the power to direct the affairs of Farnam Street Capital. No fees or other consideration will be paid by us to the Standby Purchasers in exchange for their commitment to purchase any and all unsubscribed shares of Common Stock following the rights offering.

Table of Contents

The rights offering will be made through a distribution to our existing shareholders of non-transferable subscription rights to purchase their pro rata portion of newly issued shares of Common Stock. The subscription price has not yet been determined but is expected to be based on a percentage discount of the closing market price of the Common Stock, as reported by the NASDAQ Capital Market, on the latest practicable date prior to the launch of the rights offering. The record date for the distribution of the rights and the dates for both the subscription period and the expiration of the rights offering will be included in the final prospectus that will be filed with the Securities and Exchange Commission (“SEC”).

We intend to use the net proceeds from the Rights Offering to pursue strategic opportunities that may present themselves from time to time or, if not used to pursue strategic opportunities, for working capital and general corporate purposes, including to fund ongoing research and development and product initiatives. Also, to the extent net proceeds of the Rights Offering are not deployed, some of the funds may be invested in accordance with the terms of our Surplus Capital Investment Policy.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and Chief Financial Officer (the principal executive officer and principal financial officer, respectively) conducted an evaluation of the design and operation of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)). The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on that evaluation as of December 31, 2013, our Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures are effective.

Changes in Internal Control over Financial Reporting

During the three months ended December 31, 2013, there were no changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Inherent Limitations on the Effectiveness of Controls

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

PART II

OTHER INFORMATION

Item 1. Legal Proceedings.

In February 2011, we became aware of a report entitled “Site Discovery Report, Southeast Santa Ana Project DTSC – Cypress Region,” dated February 2010 (the “Report”), that was prepared by the Cypress regional office of the Cal/EPA Department of Toxic Substances Control (“DTSC”) for Region 9 of the U.S. Environmental Protection Agency (“USEPA”) under an agreement between the two agencies. The purpose of the Report was to identify sites within an area of southeast Santa Ana, California that may be sources of groundwater contamination previously detected in that area. The Report identified 25 sites, including our former Santa Ana site, for further screening by DTSC staff. DTSC has informed us that no further evaluation of our former site has taken place subsequent to the Report’s issuance. It is uncertain whether future developments, if any, from DTSC’s screening process would have any application to our former site.

In general, we are from time to time a party to various legal proceedings incidental to our business, none of which we consider may be material. There can be no certainty, however, that we may not ultimately incur liability or that such liability will not be material and adverse.

Table of Contents

Item 1A. Risk Factors.

In addition to the information set forth in this report, you should carefully consider the risk factors discussed in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for our fiscal year ended June 30, 2013. The risks discussed in this report and in our Annual Report on Form 10-K could materially affect our business, financial condition and future results. The risks discussed in this report and in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition or operating results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibits:

Standby Purchase Agreement, dated December 17, 2013, between the Registrant and AO Partners, LLC and 10Farnam Street Capital, Inc. (incorporated by reference to Exhibit 10.1 to the Form S-3 Registration Statement filed by the Registrant on December 17, 2013)

³¹ Certification of Chief Executive Officer and Chief Financial Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

³² Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS** XBRL Instance Document

101.SCH** XBRL Taxonomy Extension Schema Document

101.CAL** XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF** XBRL Taxonomy Extension Definition Linkbase

101.LAB** XBRL Taxonomy Extension Label Linkbase

101.PRE** XBRL Taxonomy Extension Presentation Linkbase

Pursuant to applicable securities laws and regulations, the Company is deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and are not subject to liability under any anti-fraud provisions of the federal securities laws as long as the Company has made a good faith attempt to comply with the submission requirements and promptly amend the interactive data files after becoming aware that the interactive data files fail to comply with the submission requirements. Users of this data are advised that, pursuant to Rule 406T, these interactive data files are deemed not filed and otherwise are not subject to liability.

Table of Contents

SIGNATURES

In accordance with the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 6, 2014

Dated: February 6, 2014

PRO-DEX INC.

PRO-DEX INC.

By: /s/ Harold A. Hurwitz

By: /s/ Harold A. Hurwitz

Harold A. Hurwitz

Harold A. Hurwitz

Chief Executive Officer

Chief Executive Officer Secretary and Chief Financial Officer

(Principal Executive Officer)

(Principal Financial and Accounting Officer)